Published: 2. December, 2025
A newly published registry study from the Region of Southern Denmark highlights a clear…
A newly published registry study from the Region of Southern Denmark highlights a clear dilemma in prehospital pain management for children:
63% of children receiving strong pain medication were treated via intravenous (IV) cannulation, a painful and invasive procedure.
⚠️ ~35% received a nasal spray, but this was typically off-label, as no approved needle-free pain-relief product exists for children in this setting.
The study also found that strong analgesics were used in only 1 out of 17 prehospital contacts with children, and doses while safe were at the lower end of recommendations, suggesting a potential risk of undertreating pain.
The need is clear: unnecessary needle procedures should be reduced, and off-label workarounds replaced with approved, evidence-based solutions. Demand for needle-free options is high, yet current practice still relies on IV medicines repurposed for nasal use.
Cessatech’s lead asset, CT001, is being developed to provide a safe, effective, needle-free nasal spray specifically designed for children in prehospital care addressing a critical treatment gap where it matters most.
Read the full article here.
